FDA Panel Votes to Ease Restrictions on Unproven Wellness Peptides
A U.S. FDA advisory panel narrowly voted 8-6 to recommend easing restrictions on seven synthetic peptides (including BPC-157, TB-500, and Semax) for compounding pharmacy use, despite FDA scientists citing insufficient safety and efficacy data. The panel, convened under Health Secretary Robert F. Kennedy Jr., included several members with ties to the peptide industry. Critics warn the decision could expand a “Wild West” gray market, while supporters argue for patient access. The FDA is not bound by the vote but typically follows such recommendations.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection
Cross-source coverage
Wire timeline
FDA Panel Recommends Unproven Peptides, Sparking Safety Debate
An FDA advisory panel voted to recommend adding six unproven peptides to the list of drugs that compounding pharmacies can sell, despite safety and efficacy concerns. The vote was influenced by Health Secretary Robert F. Kennedy Jr., who added eight new members to the panel, six of whom run clinics offering these peptides. Proponents argue that thousands already use potentially dangerous black market peptides and that regulated access would be safer. Critics, including FDA scientists, cite a lack of clinical trial data and risk of harmful immune reactions. The decision is seen as part of a broader push to bypass strict FDA evidence standards, driven by demand from wellness influencers and celebrities. Experts warn this could open a 'Pandora's box' of untested drugs, undermining the FDA's role as a consumer protection agency.
FDA Advisory Committee Votes to Recommend Six Peptides for Compounding Pharmacy Use
The FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend adding six peptides—BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax—to the 503A bulks list, potentially allowing compounding pharmacies to produce customized medications. The vote follows growing demand for unapproved peptides promoted by wellness influencers, with U.S. imports from China doubling to $328 million in 2025. HHS Secretary Robert F. Kennedy Jr. has advocated for legal access, arguing the current ban creates a dangerous black market. The committee rejected emideltide for opioid withdrawal and insomnia. FDA scientists had recommended against the additions due to insufficient safety evidence. The FDA typically follows committee advice but final regulations could take months or years.
FDA Advisory Committee Votes to Recommend Six Peptides for Compounding Pharmacy Use
The FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend adding six peptides—BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax—to the 503A bulks list for specific uses, potentially allowing compounding pharmacies to produce customized medications. The committee voted against recommending emideltide for opioid withdrawal and sleep disorders. The vote comes amid a growing gray market for peptides, with imports from China doubling to $328 million in the first three quarters of 2025. HHS Secretary Robert F. Kennedy Jr., a self-described 'big fan of peptides,' had previously removed 12 peptides from a banned Category 2 list for re-evaluation. FDA scientists opposed the recommendation, citing insufficient safety and efficacy evidence. At least seven PCAC members had financial ties to the peptide industry. The FDA is not bound by the vote but typically follows committee recommendations; final regulations could take months or years.
Show 4 older updatesHide older updates
FDA Advisers Narrowly Back Easing Access to Wellness Peptides Despite Safety Warnings
A Food and Drug Administration (FDA) advisory panel voted 8-6 on Thursday to recommend easing restrictions on several injectable peptides popular with wellness influencers, including BPC-157, TB-500, and KPV. The vote came despite strong objections from FDA scientists who cited a lack of evidence for safety or effectiveness. The panel's makeup was unusual, with over half a dozen members having ties to the peptide industry. The recommendation is not binding but is expected to embolden Health Secretary Robert F. Kennedy Jr., a self-described 'big fan' of peptides who has already removed these substances from a high-risk compounding list. Supporters argue for patient and physician autonomy, while critics warn of a 'Wild West' of unproven, potentially dangerous substances. The FDA typically follows panel advice but is not required to do so. Further votes on three more peptides are scheduled.
FDA panel narrowly backs unapproved peptide drugs favored by RFK Jr and wellness influencers
A U.S. Food and Drug Administration (FDA) advisory panel narrowly voted 8-6, with one abstention, to recommend easing restrictions on several unapproved injectable peptides, including BPC-157, TB-500, and KPV. These peptides are popular with wellness influencers and Health Secretary Robert F. Kennedy Jr., who has vowed to overturn FDA restrictions. Despite the vote, FDA scientists expressed strong concerns, stating there is little data on the safety or effectiveness of these peptides for proposed uses such as ulcerative colitis, wound healing, and opioid addiction. The panel's unusual makeup included several members with ties to the peptide industry. If the FDA follows the advice, telehealth companies are expected to increase marketing of these substances. Medical experts warn of serious risks including infection and allergic reactions, describing the peptide marketplace as a 'Wild West' of unproven drugs.
Inside the unconventional FDA panel that could reshape the peptide industry
An unconventional FDA advisory committee, convened under Robert F. Kennedy Jr.'s leadership, is meeting to assess the safety and efficacy of seven previously-banned peptides popular in fitness and wellness circles. The panel includes members who prescribe, research, or sell peptide therapies, raising conflict-of-interest questions. On the first day, the panel voted to approve BPC-157 (the 'wolverine' shot) for recovery and wound healing. Other compounds under review include TB-500 and epitalon. The FDA argues these peptides lack sufficient safety and efficacy evidence, while industry leaders advocate for consumer-driven access and a safer supply chain, potentially opening a multibillion-dollar market.
U.S. FDA Panel to Review Peptide Compounding Amid Safety and Gray Market Concerns
A U.S. Food and Drug Administration review panel is set to consider whether seven synthetic peptides, including BPC-157, TB-500, and Semax, should be recommended for compounding. These substances were restricted under the Biden administration due to a lack of human clinical trial data. Despite the restrictions, peptides are widely available online from chemical suppliers for 'lab use only,' fueling a gray market with no oversight. Wellness influencers and Health Secretary Robert F. Kennedy Jr., who has used peptides for injuries, argue the restrictions drive consumers to unregulated overseas suppliers. Medical experts warn that evidence for safety and efficacy is insufficient, and a white paper by ECRI and ISMP called the lack of clinical evidence an 'alarming safety concern.' Critics accuse Kennedy of stacking the advisory panel with industry-linked members, raising doubts about the outcome.